Bullish option flow detected in Novavax (NVAX) with 10,455 calls trading, 2x expected, and implied vol increasing over 6 points to 78.51%. 3/14 ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax (NVAX) announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, ...

Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has earned an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst ...

Market forces rained on the parade of Novavax, Inc. (NASDAQ:NVAX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker.

Novavax Inc. closed 65.72% short of its 52-week high of $23.86, which the company achieved on June 6th.